Under CMS’s six-month moratorium on new enrollments, I have effectively been told to sit still, burn cash, and hope I survive long enough to eventually serve patients. That is not good policy. That is ...

The question is not how clinicians can be made more resilient. It is why an institution performing at the highest level of ...

Foreign reference pricing frameworks often differ from the way the US has historically valued medical innovation. A more ...

Perhaps the term “better” should not be defined by business metrics at all—but instead by the innovation’s health impacts ...

The proposed changes are relatively modest, yet they represent an important procedural step forward in the implementation of ...

California cannot control whether mifepristone will remain available at the national level. But it can control whether ...

Having been stymied by courts elsewhere. the Justice Department has turned to a conservative federal district court in Texas ...

Congress should require the FDA to make DSCSA traceability data accessible and interpretable not only by regulatory agencies ...

Rather than impose one-size-fits-all solutions, federal and state policy makers should craft Medicaid payment policies that ...

Nasal naloxone remains expensive relative to the cost of the underlying drug and continues to strain budgets of public health ...

Using heart failure as an example, we explore technical issues with episode-based payments that are best resolved within the ...

If an HHS Secretary can seek to unilaterally overturn an evidence-based standard of transgender health care, the same can ...